Previous 10 | Next 10 |
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His in...
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CP...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q1 GAAP EPS of -$0.18. As of March 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $62.9 million For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.18
BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are adva...
BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs...
Penny stocks are a great way to quickly make money in the stock market. Today we are looking at a handful that insiders including top management have decided to scoop up as the second quarter begins. The topic of stocks with insider activity has become a bigger point of focus for trader...
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2021 Earnings Conference Call March 10, 2022 04:30 PM ET Company Participants Richard Miller - Co-Founder, President and CEO Leiv Lea - CFO Zack Kubow - Investor Relations, Real Chemistry Conference Call Participants Li Watsek - Cantor Fitzgerald Mara Go...
Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q4 GAAP EPS of -$0.20 misses by $0.01. Q4 Cash and cash equivalents $69.45M For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01
BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. ...
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trial...
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update an...
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th 17 cells into anti-inflammatory T reg cells Publication confirms and extends understanding of ITK inhibition mechanism of action and its potent...